Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Applying for dermatology residency is difficult and expensive

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Medicaid acceptance among pediatric dermatologists

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Adult-onset Still's disease revealed by facial edema

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A. David Burden, MD, Michael Rissler, PhD, Christian Sieder, PhD, Roberto Orsenigo, MD, Kamel Chaouche-Teyara, PhD Journal of the American Academy of Dermatology Volume 80, Issue 5, Pages 1344-1352 (May 2019) DOI: 10.1016/j.jaad.2019.01.066 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 2PRECISE study design and patient disposition. This was a phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study. AE, Adverse event; TP2, treatment period 2. Journal of the American Academy of Dermatology 2019 80, 1344-1352DOI: (10.1016/j.jaad.2019.01.066) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Proportion of subjects (full analysis set 1, all patients, last observation carried forward) achieving a 75% improvement from baseline in the Palmoplantar Psoriasis Area Severity Index score (PPPASI75) through week 16. The primary end point was not met, but clinical benefit was observed with secukinumab, 300 mg, with 26.6% of subjects achieving PPPASI75 at week 16. Journal of the American Academy of Dermatology 2019 80, 1344-1352DOI: (10.1016/j.jaad.2019.01.066) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Improvements in the rate of achievement of a 75% improvement from baseline in the Palmoplantar Psoriasis Area Severity Index (PPPASI75) with secukinumab were observed to continue to week 52. Journal of the American Academy of Dermatology 2019 80, 1344-1352DOI: (10.1016/j.jaad.2019.01.066) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions